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Summary (200 words) 
There is an urgent need to discover new anti-tubercular agents with novel mechanisms of action in 
order to tackle the scourge of drug-resistant tuberculosis. Here, we report the identification of such a 
molecule – an AminoPYrimidine-Sulfonamide (APYS1) that has potent, bactericidal activity against M. 
tuberculosis. Mutations in APYS1-resistant M. tuberculosis mapped exclusively to wag31, a gene that 
encodes a scaffolding protein thought to orchestrate cell elongation. Recombineering confirmed that 
a Gln201Arg mutation in Wag31 was sufficient to cause resistance to APYS1, however, neither 
overexpression nor conditional depletion of wag31 impacted M. tuberculosis susceptibility to this 
compound. In contrast, expression of the wildtype allele of wag31 in APYS1-resistant M. tuberculosis 
was dominant and restored susceptibility to APYS1 to wildtype levels. Time-lapse imaging and 
scanning electron microscopy revealed that APYS1 caused gross malformation of the old pole of M. 
tuberculosis, with eventual lysis. These effects resembled the morphological changes observed 
following transcriptional silencing of wag31 in M. tuberculosis. These data show that Wag31 is likely 
not the direct target of APYS1, but the striking phenotypic similarity between APYS1 exposure and 
genetic depletion of Wag31 in M. tuberculosis suggests that APYS1 might indirectly affect Wag31 
through an as yet unknown mechanism. 
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Introduction 
Tuberculosis (TB) is the leading bacterial infection impacted by drug resistance in the world today, 
with 480,000 cases of multidrug resistant (MDR) TB, comprising 3.6% of all new incident cases of TB, 
recorded each year (WHO, 2015). In addition to this, extensively drug resistant (XDR) TB has been 
reported in more than 105 countries (WHO, 2015) and totally drug resistant (TDR) TB (Velayati et al., 
2009), for which treatment options are similar to those in the pre-antibiotic era, is becoming 
increasingly common. Whilst the discovery and introduction of the novel anti-tuberculosis drugs 
bedaquiline and delamanid are welcome developments and will provide some relief, the fact that 
anti-tubercular drug discovery and development lags far behind the emergence of drug resistance is 
indefensible in light of the global burden of this disease. In order to tackle the scourge of drug-
resistant TB, it is vital that new antibiotics are discovered that exhibit novel mechanisms of action. 
Understanding the mode of action of novel antibiotic molecules serves to aid both the 
development of new drugs and to establish the vulnerability of targets in Mycobacterium 
tuberculosis against which the compounds act. This field of research is providing a growing picture of 
new vulnerable and druggable targets in M. tuberculosis, including DprEI (first found using 
benzothiazinones (Makarov et al., 2009)), DnaN (the target of griselimycin (Kling et al., 2015)), ClpC1 
(the target of cyclomarin A (Schmitt et al., 2011)), ClpP (the target of cyclic acyldepsipeptides, ADEPs 
(Ollinger et al., 2012)), cytochrome bc1 (Q203 (Pethe et al., 2013) and lansoprazol sulfide (Rybniker 
et al., 2015)) and AtpE (the target of bedaquiline (Andries et al., 2005)). 
Here we describe the discovery of a novel anti-TB compound through phenotypic screening 
of a compound library against replicating M. tuberculosis, and the use of next-generation sequencing 
to demonstrate that resistance is mediated exclusively through mutations in the cell division protein, 
Wag31. Follow-up experiments using a combination of chemical genetics, time-lapse microscopy and 
scanning electron microscopy, shed light on the novel, and atypical mechanism of action of this 
antibiotic. 
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Results 
Aminopyrimidine-sulfonamides (APYS) are potent anti-tubercular compounds 
A medium-throughput screen of 15344 small molecules identified a series of three similar 
AminoPYrimidine-Sulfonamides (APYS1-3) with potent activity against replicating M. tuberculosis 
H37Rv, and limited cytotoxicity against a panel of cell lines (Figure 1; Table S1). The most potent of 
these compounds (APYS1) was subsequently shown to be bactericidal with a minimal bactericidal 
activity (MBC99) of 0.6 µM, similar to its minimal inhibitory concentration (MIC) of 0.3 – 0.6 µM. 
Further characterisation of these compounds showed that APYS1-3 did not display any activity 
against non-replicating M. tuberculosis, as determined using the streptomycin-starved 18b model 
(Sala et al., 2010), suggesting that these compounds target a process essential for cell growth. APYS1 
was also found to be inactive against intracellular H37Rv in both RAW macrophages (up to 20 µM), 
and in fibroblasts (up to 100 µM). Interestingly, omission of Tween 80 from Middlebrook 7H9 
medium significantly impacted the MIC of APYS1-3 (16-fold increase in MIC99), suggesting that this 
detergent might facilitate entry of the compound into H37Rv, and providing a possible explanation 
for the lack of intracellular activity of the compound. All activity data were confirmed with newly 
synthesised and purified APYS1-3 compounds (See Supplementary Chemistry for details of chemical 
synthesis). No significant synergy was observed between APYS1 and standard anti-tubercular 
compounds (Table S2). In additional experiments, APYS1 was also found to be active against 
Mycobacterium smegmatis, albeit only in the presence of an efflux inhibitor (Supplementary Results). 
As APYS1 was the most potent of the APYS series, this molecule was taken forward for further 
investigation into its activity profile and mechanism of action. 
Mutations in wag31 are causal of APYS1 resistance in M. tuberculosis 
To understand the mechanism of action of APYS1, spontaneous APYS1-resistant mutants of M. 
tuberculosis H37Rv were isolated independently at two laboratories. Resistant clones were selected 
on 30 µM APYS1 (100x MIC) at a frequency of 6 x 10
-7
. Eleven individual APYS1-resistant clones 
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(ARC1-11) were picked, grown without APYS1 and confirmed to be resistant to APYS1 by the 
resazurin reduction microplate assay (REMA) (Table 1), whilst not exhibiting cross-resistance to other 
TB drugs (rifampicin, isoniazid, ethambutol, p-aminosalicylic acid, streptomycin and levofloxacin; 
data not shown). Whole genome sequence analysis of wildtype H37Rv and three APYS1-resistant 
clones (ARC1-3) revealed that the three resistant clones carried different non-synonymous mutations 
in wag31, which codes for the M. tuberculosis “division protein” Wag31 (also known as DivIVA or 
Ag84). These wag31 mutations were confirmed by Sanger sequencing. Targeted sequencing of the 
eight other resistant isolates (ARC4-11) revealed that they all carried non-synonymous mutations at 
different positions in wag31 (Table 1). The growth rates of all of the resistant strains in the absence 
of APYS1 were indistinguishable from that of the parental M. tuberculosis strain (data not shown). 
Wag31 is an essential protein in M. tuberculosis (Sassetti et al., 2003). It has no known 
enzymatic activity, but is hypothesised to act as a scaffolding protein that localises to the poles of the 
bacterium and allows for the proper assembly and function of the elongation machinery (Kang et al., 
2008). The more highly conserved N-terminal domain of Wag31 includes the lipid binding domain 
(LBD) which, in the Bacillus subtilis homologue, is important for its polar membrane localisation (van 
Baarle et al., 2013). In addition, the activity of Wag31 has been shown to be modulated through 
phosphorylation of threonine 73 (T73) by the Ser/Thr protein kinases, PknA and PknB (Jani et al., 
2010). All eleven APYS1 resistance mutations were, however, located distal to the N-terminus and 
clustered between Lys190 and Arg213 (Figure 2A and Table 1), strongly implying a fundamental role 
for this region in the mechanism of resistance, and potentially, in the mechanism of action, of APYS1 
(Figure 2, Table1). Overall, the C-terminal domain of Wag31 is less conserved amongst different 
species of bacteria, with the resistance-determining region (RDR) being restricted to mycobacteria 
and close relatives. Interestingly, the residues mutated in APYS1-resistant mutants are conserved 
within the Wag31 homologues of the mycobacterial species analysed (Figure 2). The C-terminal 
domain is predicted to form a long alpha helix/coil and a helical wheel simulation clustered the 
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APYS1 mutations mainly on the same side of the helix, which is largely hydrophobic and therefore 
possibly protected from the aqueous environment by unknown protein-protein interactions. 
A Gln201Arg (Q201R) mutation in Wag31 is sufficient to confer resistance of H37Rv to APYS1 
To establish whether a single non-synonymous mutation in wag31 is sufficient to confer resistance of 
M. tuberculosis to APYS1, site-directed mutagenesis of the native chromosomal copy of wag31 was 
performed by recombineering in H37Rv. A long primer that carried both the non-synonymous 
mutation (a602g, Q201R) and a synonymous mutation (g609c: to confirm that the Q201R mutation 
was primer-derived and not the result of spontaneous mutation) was used. APYS1-resistant colonies 
were readily selected and Sanger sequencing confirmed the presence of both mutations in wag31, 
thus corroborating that they arose from recombineering. A selected recombinant colony 
(H37Rv::Rec-wag31
Q201R
) was evaluated and found to be resistant to APYS1 (Table1, MIC90 >100 µM),
as well as APYS2 and APYS3, while showing unaltered susceptibility to moxifloxacin. Thus, a single 
non-synonymous mutation in wag31 is sufficient to cause APYS1 resistance in M. tuberculosis. 
Effect of overexpression of wag31 or wag31Q201R on the susceptibility of M. tuberculosis to APYS1 
To determine the impact of wag31 overexpression in M. tuberculosis on APYS1 susceptibility, a 
second copy of either wildtype wag31 or wag31
Q201R
 under control of the native wag31 promoter, 
was integrated into both wildtype H37Rv and the APYS1-resistant mutant, ARC4. Western blot 
analysis confirmed that the concentrations of the Wag31 and Wag31
Q201R
 proteins in the 
recombinant strains were approximately twice that of the control strain (Figure S1). Surprisingly, 
overexpression of the wildtype allele of wag31 in H37Rv did not significantly modulate APYS1 
susceptibility (Table 1). In addition, overexpression of wag31
Q201R
 in either H37Rv or ARC4 did not 
impact their susceptibilities to APYS1 (Table 1). However, expression of wildtype wag31 in ARC4 
restored the APYS1 susceptibility of this mutant to near wildtype levels (Table 1). These results show 
that wildtype wag31 is dominant for the susceptibility of H37Rv to APYS1, and expression of 
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additional mutant or wildtype copies of wag31 does not significantly modulate activity thus implying 
that APYS1 is not a direct inhibitor of Wag31. 
Conditional depletion of wag31 does not affect susceptibility of M. tuberculosis to APYS1 
Classically, inhibitors of enzymes involved in cellular metabolism become more potent when the 
cellular concentration of the enzyme is reduced (Evans and Mizrahi, 2015). A similar phenotype may 
also be expected for a scaffolding protein such as Wag31, although this has not been previously 
shown. We thus set out to assess the impact of the conditional depletion of Wag31 on the 
susceptibility of M. tuberculosis to APYS1. Conditional mutants were constructed by replacing the 
native wag31 promoter (Pwag31) with a tetracycline (Tet)-regulated promoter (Pmyc1tetO) (Ehrt et 
al., 2005) (Figure S2), controlled by either the forward Tet repressor (TetR) or reverse Tet repressor 
(rev-TetR), to produce mutants in the Tet-ON (wag31 Tet-ON) or Tet-OFF (wag31 Tet-OFF) 
configuration, respectively. Both  wag31 Tet-ON and wag31 Tet-OFF configurations showed ATc 
dependent growth (Figure 3), confirming the predicted essentiality of wag31 in M. tuberculosis 
(Sassetti et al., 2003; Griffin et al., 2011), although only the Tet-OFF configuration fully repressed 
growth and Wag31 protein production (>100 ng/mL of ATc,  Figure 3C). ATc had no measurable effect 
on growth of the parental H37Rv or wag31-SCO strains over the concentration range tested. 
Potential synergy between Wag31 depletion and APYS1 activity was investigated using a 
checkerboard assay on the M. tuberculosis wag31 Tet-OFF mutant. However, no synergy was 
observed, even at concentrations of ATc (60-80 ng/mL, Figure 3B) where significant inhibition of 
growth of the wag31 Tet-OFF mutant was observed. Synergy was also not seen when wag31 was 
silenced 2 days prior to APYS1 exposure (data not shown). Wag31 depletion therefore did not 
sensitize M. tuberculosis to the toxic effects of APYS1, supporting the conclusion that APYS1 does not 
directly target Wag31. 
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APYS1 does not affect mycobacterial cell envelope lipids 
Two recent studies showed that acetyl-CoA carboxylases (ACCase) co-localize with, and bind to, 
Wag31 in M. smegmatis (Meniche et al., 2014; Xu et al., 2014). ACCase plays a crucial role in the 
synthesis of malonyl-CoA, the building block for both fatty acids and mycolic acids in mycobacteria. 
To investigate whether APYS1 treatment interferes with Wag31-ACCase interactions, a detailed 
analysis of fatty acid and mycolic acid production was performed by metabolic labelling (
14
C-acetate) 
of lipids in M. tuberculosis H37Ra (an avirulent strain that is equally susceptible to APYS1 as H37Rv; 
MIC90 = 0.25 – 0.5 µM). This analysis revealed that APYS1 treatment had no effect on the total 
formation of either fatty acids or mycolic acids (Figure S4). Moreover, APYS1 had no effecton the 
total incorporation of 
14
C-acetate into lipids, however an increase was observed in the extractable 
lipid compared to cell bound lipids (likely an indirect result of APYS1 treatment). Additional analyses 
revealed no major impact of APYS1 on other prominent cell envelope lipids including trehalose 
monomycolate (TMM), trehalose dimycolate (TDM), phosphatidylethanolamine (PE), 
phosphatidylinositol (PI) and phosphatidylinositol mannosides (acyl1-2PIM2) (Figure S4). Overall, these 
data suggest that it is unlikely that APYS1 affects interactions between Wag31 and ACCases. 
Single-cell analysis of the effects of APYS1 treatment on M. tuberculosis 
It has been shown in M. smegmatis that the modulation of wag31 expression has a significant impact 
on the morphology of the bacterial poles (Nguyen et al., 2007; Kang et al., 2008). Given the evidence 
implicating Wag31 in the mechanism of resistance of APYS1, we evaluated the effect of APYS1 on M. 
tuberculosis growth and morphology using a microfluidic device coupled to time-lapse microscopy 
(Wakamoto et al., 2013; Dhar and Manina, 2015). For these experiments, the Erdman strain (another 
wildtype M. tuberculosis strain with the same susceptibility to APYS1 as H37Rv) was grown initially in 
APYS1-free medium for 3 days, and then exposed to 6 µM APYS1 for 7 days (between 72-235 h of 
the time-lapse experiment) before the compound was washed out to allow any survivors to grow. 
The images revealed that following 24h of APYS1 exposure, the bacterial poles started to swell and 
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become globular (Figure 4, Movies S1A and S1B). Swelling was usually restricted to the polar region 
and, more specifically, to the old growing pole. Whilst the old pole swelled up, bacteria were able to 
divide once and to generate a daughter cell from their new pole, after which both mother and 
daughter cells lysed. In support of this, enumerating the bacteria as a function of time following 
exposure to APYS1 (Figure S5), showed that the bacterial population nearly doubled, before the cells 
lysed. Careful examination of the time-lapse microfluidic movies of the polar deformation of H37Rv 
caused by APYS1 treatment revealed disproportionate growth of the two lateral walls near the tip, 
leading to curling and swelling of the polar tips (Figure 4). During the 7 days’ exposure to APYS1, the 
majority of the cells lysed and continued to lyse even after washout of the compound. Among the 
different micro-colonies imaged, approximately 6% had at least one survivor that regrew normally 
after washout of the compound, and divided to give rise to normal rod-shaped cells. Interestingly, in 
all of these cases, the survivors originated from the newer-pole sibling. 
In supplementary experiments, a similar malformation of the old pole was seen by time-lapse 
microscopy of M. smegmatis in the presence of APYS1 and the efflux inhibitor verapamil, suggesting 
a similar mechanism of action of this compound in both mycobacterial species (Movie S3). 
Redistribution of Wag31-GFP upon exposure to APYS1 
Based on the association between Wag31 mutations and APYS1 resistance, the impact of APYS1 on 
Wag31 polar localization was investigated. To this end, an H37Rv merodiploid strain was constructed 
by inserting, at the attB locus, a copy of wag31 carrying a 3’-terminal gfp fusion (Erdman::wag31-gfp) 
(Santi et al., 2013). Erdman::wag31-gfp grew like the parental strain, showed no morphological 
defects, and was equally susceptible to APYS1 as the parental Erdman strain (Table 1). Imaging of 
Erdman::wag31-gfp in the GFP channel every 24h (to avoid phototoxicity) showed that, prior to 
APYS1 exposure, all cells were normal rod-shaped and showed clear polar and septal localization of 
Wag31-GFP (Day 0 in Figure 5). As observed for wildtype M. tuberculosis, within 24h of exposure to 6 
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µM APYS1, Erdman::wag31-gfp started swelling at the poles. In the presence of APYS1, Wag31-GFP 
protein remained localised to the pole, sometimes as a single focal point, and sometimes 
redistributed into several foci along the edges of the bulbous pole (Figure 5). These data showed that 
APYS1 does not affect the overall polar positioning of Wag31 within the cell, but may partially affect 
the organisation of Wag31 at the pole. 
Single-cell analysis of conditional Wag31 depletion in M. tuberculosis 
To establish whether M. tuberculosis has a similar phenotype on Wag31 depletion as previously 
published in M. smegmatis (Kang et al., 2008), and to compare this effect with that of APYS1 
exposure, time-lapse microscopy was carried out on the conditional knockdown mutant, wag31 Tet-
OFF. Bacteria were grown initially in absence of ATc (Movies S2A and S2B) until they formed small 
microcolonies (3 days), and were subsequently exposed to 2 µg/ml ATc for 7 days (between 75-242 h 
in the experiment shown in Figure 6). Single-cell analysis showed that bacteria continued to grow 
and divide normally without any morphological impact for 80-100 h following the addition of ATc. 
This lag probably reflects the time required to deplete the previously synthesized protein (in 
agreement with the Western blot analysis shown in Figure 3C). Following this lag however, cells 
started to swell at their poles, round up and continued to bloat until they burst. Interestingly, and in 
contrast to APYS1-treated bacteria, the newer pole siblings of the ATc-treated wag31 Tet-OFF 
mutant were more likely to become globular compared to the older pole sibling, which also swelled 
but tended to lyse before becoming fully rounded. A small fraction of cells that remained intact 
during ATc exposure regrew after washout of ATc and gave rise to normal rod-shape daughters. 
Electron microscopy of M. tuberculosis treated with APYS1 
Scanning electron microscopy (SEM) was used to analyse the impact of APYS1 on H37Rv at high 
resolution. Whilst control bacteria are classically rod-shaped, exposure of H37Rv to APYS1 for 24-h 
led to gross malformation of the polar extremity of the bacilli in a manner similar to that observed in 
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the time-lapse experiments. From the images shown in Figure 7, it is clear that the swelling of the cell 
occurs largely away from the septum, at the old pole. In addition, the SEM images clearly confirmed 
that in cases where a daughter cell had recently separated, it remained rod-shaped (Figure 7B, D and 
E). The exact shape of the swollen cell pole was variable, with images revealing general polar swelling 
(Figure 7D), a swollen tight “corkscrew” spiral (Figure 7E), and a swollen open spiral (Figure 7F). 
Though the exact cause of the different forms of swelling is not understood, these findings are 
consistent with the microfluidics experiments where different degrees of swelling were observed. 
The SEM data clearly provide a high-resolution visualisation of the polar deformation of M. 
tuberculosis caused by APYS1, and strongly reinforce the role of this compound in disrupting the 
integrity of the mycobacterial cell wall. 
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Discussion 
Tuberculosis is a global health problem, and the bacterial infection most impacted by multidrug 
resistance. It is therefore essential to discover new classes of antibiotic, and to gain insight into their 
underlying mechanisms of action in order to identify and exploit new vulnerabilities in M. 
tuberculosis.  Here, we report the discovery of a novel anti-tubercular, APYS1, and utilise a 
combination of genetic and microscopy techniques to investigate its mechanism of action. 
Elucidating the mechanism by which a susceptible bacterium becomes resistant to an antibiotic is a 
powerful means of gaining insight into its mode of action. Generally, resistance mutations are either 
associated with the antibiotic target itself; linked to a mechanism by which the bacterium can 
eliminate or detoxify the antibiotic, largely through increased antibiotic efflux or metabolic 
inactivation; or, in the case of a prodrug, located in a gene(s) involved in its metabolic activation. Our 
data clearly show that single point mutations clustered within a region of wag31 can render M. 
tuberculosis resistant to the anti-tubercular activity of APYS1. However, overexpression of a second 
copy of either the mutant or wildtype wag31 allele in wildtype M. tuberculosis did not impact APYS1 
susceptibility. Moreover, transcriptional silencing of wag31 transcription in M. tuberculosis did not 
synergise with the activity of APYS1. These findings suggest that while wag31 is clearly involved in 
the mechanism of resistance to APYS1, Wag31 itself is not the direct target of APYS1.However, a 
pivotal observation was that expression of wildtype wag31 in a resistant isolate of H37Rv (ARC4, 
carrying a Gln201Arg mutation in wag31), was dominant, and reverted the APYS1-resistant 
phenotype of ARC4 to susceptible (i.e., complemented resistance). This indicates that the presence 
of a wildtype wag31 allele is sufficient for APYS1 activity, even though this activity cannot be 
modulated by decreasing or increasing wag31 expression in wildtype H37Rv. To our knowledge, this 
phenotype has not been observed previously with any chemical compounds in bacteria, and clearly 
suggests an atypical and novel mechanism of action. A possible explanation is that APYS1 binds 
another protein and that this complex (APYS1-protein X) interacts with wildtype Wag31, causing cell 
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death. The resistance mutations in Wag31 would prevent the binding of APYS1-protein X and 
therefore prevent cell death. However, it remains unclear as to why such an interaction cannot be 
titrated. 
Wag31 is a scaffolding protein that binds to the negative curvature of the polar cell wall (Lenarcic et 
al., 2009; Ramamurthi and Losick, 2009; Oliva et al., 2010), and allows for the correct placement and 
coordination of partner proteins for elongation and the biosynthesis of cell wall precursors (Nguyen 
et al., 2007; Meniche et al., 2014). In M. tuberculosis, Wag31, is present exclusively at growing poles, 
and is  recruited to the new pole only after the septum has been formed (Santi et al., 2013). Previous 
work has demonstrated that conditional depletion of wag31 was associated with the swelling and 
deformation of the bacterial pole in M. smegmatis (Kang et al., 2008). Time-lapse microscopy of 
single cells clearly demonstrated that conditional depletion of Wag31 in M. tuberculosis had a very 
similar effect, with this imaging modality revealing swelling/bulging of the bacterial “new” pole and 
eventual bacterial lysis. Interestingly, exposure of M. tuberculosis and M. smegmatis to APYS1 also 
resulted in a very clear and similar swelling/bulging of the bacterial pole, however, in this case, it was 
primarily the “old” pole that was affected. The differential polar deformation between Wag31 
depletion and APYS1 exposure is likely due to differences in the effects of conditional protein 
depletion versus compound activity. Specifically, arrest of de novo production of Wag31 by 
transcriptional silencing of wag31 would have little impact on the old pole where Wag31 is already 
present, but would primarily impact the new pole to which Wag31 is recruited after septum 
formation. In contrast, perturbation of Wag31 or its associated function by a compound such as 
APYS1 is likely to act where Wag31 is already active, and hence, demonstrate a preference for the 
older, elongating pole. Visualisation of the distribution of Wag31-GFP showed that Wag31 remained 
localised at the poles following the addition of APYS1, although in some cases there was a 
redistribution of the protein at the old pole. Moreover, instead of swelling evenly, some of the poles 
continued to elongate along one side causing the tips to curl – a phenotype perhaps associated with 
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the localisation of Wag31 and confirmed in SEM images. Although the genetic studies argued against 
Wag31 being the direct target of APYS1, time-lapse microscopy showed significant morphological 
similarities between APYS1 treatment  and Wag31 depletion, suggesting that Wag31 may play an 
important role in the mechanism of action of APYS1, albeit not as the direct target. 
Conditional depletion of Wag31 is likely to lead to inadequate scaffolding and orchestration of cell 
elongation, potentially through the inability to co-ordinate the positioning of partner proteins, 
leading to weakening of the cell wall and polar bulging. Given the role of wag31 mutations in 
conferring resistance to APYS1, and the similar effects of Wag31 depletion and APYS1 treatment on 
mycobacterial morphology, one could postulate that APYS1 acts by affecting the binding of one or 
more partner proteins to Wag31. This hypothesis is supported by the spatial clustering of the APYS1 
resistance mutations on one hydrophobic flank of the Wag31 helix, suggestive of a site for protein-
protein interactions.  Wag31 has been reported to interact with proteins of the ACCase complex 
involved in cell envelope lipid formation (Meniche et al., 2014), the protein kinase, PknB (Kang et al., 
2005; Kang et al., 2008), and a small uncharacterised Mycobacterium-specific protein, CwsA 
(Plocinski et al., 2012; Plocinski et al., 2013). Our analysis of cell envelope lipids showed that it is 
unlikely that APYS1 affects an interaction with the ACCase complex. Interestingly, however, 
conditional depletion or overexpression of PknB has been shown to cause swelling of M. smegmatis 
(Kang et al., 2005; Kang et al., 2008; Chawla et al., 2014), and overexpression of CwsA likewise 
resulted in polar swelling in both E. coli and M. smegmatis through an unknown mechanism 
(Plocinski et al., 2013). Thus, APYS1 may act to perturb Wag31::PknB or Wag31::CwsA interactions, 
although it is unclear as to why these interactions cannot be titrated by depletion or overexpression 
of Wag31.  It is worth noting that APYS1 shares a similar chemical scaffold to navitoclax, a largely 
linear molecule with a 4-aminobenzene-1-sulfonamidecore, that is an effective inhibitor of protein-
protein interactions between the human apoptosis regulatory protein, BCL-2, and its pro-apoptotic 
partner, BAX (Souers et al., 2013; Arkin et al., 2014). 
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Alternatively, APYS1 might affect M. tuberculosis through an as yet undefined mechanism associated 
with Wag31. As an example, the bulging of the mycobacterial cell pole is reminiscent of deformations 
observed following weakening of the peptidoglycan component of the cell wall by the β-lactam 
antibiotic, meropenem (Chao et al., 2013); by conditional depletion of the penicillin binding protein, 
PonA (Kieser et al., 2015); or by overexpression of the active form of the peptidoglycan hydrolase, 
RipA (Chao et al., 2013). Wag31 has previously been suggested to co-ordinate peptidoglycan 
synthesis (Nguyen et al., 2007; Kang et al., 2008), and a recent report showed that in M. smegmatis 
Wag31 was enriched in the fraction containing plasma membrane tightly associated to the cell wall 
fraction (PM-CW) rather than the pure plasma membrane fraction (PMf) (Hayashi et al., 2016), which 
hints at the possibility of Wag31 to interact directly with periplasmic proteins involved in 
peptidoglycan biosynthesis. Future studies that build upon on these observations, are likely to shed 
light on the exact mechanism through which APYS1 acts. 
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Experimental Procedures: 
Isolation of H37Rv resistant mutants to APYS1 
Spontaneous mutants of H37Rv resistant to APYS1 were isolated in parallel at two different research 
sites. Briefly wildtype H37Rv (10
8
 or 10
9
 CFU) was plated on Middlebrook 7H10 or 7H11 agar 
supplemented with 0.5 % glycerol and 10% OADC, and containing APYS1 (10x, 20x, 50x and 100x 
MIC). Following incubation (4 weeks, 37˚C), colonies were selected and sub-cultured in Middlebrook 
7H9 broth (supplemented with 0.2 % glycerol, 0.05% Tween 80 and 10% ADC). Selected isolates were 
screened for their susceptibility to APYS1 as well as rifampicin, isoniazid, ethambutol, p-
aminosalicylic acid, streptomycin and levofloxacin. The parental H37Rv strain and three resistant 
isolates with confirmed resistance to APYS1 were subjected to whole-genome sequencing on 
Illumina HiSEQ sequencer (as per manufacture’s protocol), and single nucleotide polymorphisms 
identified using HTStation (David et al., 2014). Mutations identified in wag31 (Rv2145c/divIVA) were 
confirmed by Sanger sequencing, and tested in the remaining 8 resistant isolates that did not 
undergo whole genome sequencing (Primers Wag31 seq F and Wag31 seq R, Table S3). 
Construction of H37Rv and ARC4 carrying a second copy of wag31 or wag31
Q201R
 
Wild type wag31 and wag31
Q201)
 with the native promoter (149 bp 5’-terminal to the start codon of 
wag31) were PCR amplified using the primers listed in Table S3, from parental H37Rv and APYS1-
resistant ARC4. The amplified product was digested with EcoRI and cloned into the integrative shuttle 
plasmid pTT1B::Gm (Abrahams et al., 2012) to generate pTTwag31 and pTTwag31
(Q201R)
 respectively. 
Control plasmid pTT1B, pTTwag31 and pTTwag31
(Q201R)
 were electroporated into H37Rv and ARC4 to 
produce H37Rv::pTT1B, H37Rv::pTTwag31, H37Rv::pTTwag31
(Q201R)
, ARC4::pTT1B, ARC4::pTTwag31 
and ARC4::pTTwag31
Q201R
 respectively. The susceptibility of these strains to APYS1 was then 
determined by REMA. 
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Time-lapse microscopy 
Time-lapse microscopy of wildtype M. tuberculosis (Erdman), the M. tuberculosis strain expressing 
Wag31-GFP (Erdman::wag31-gfp) and wag31 Tet-OFF was carried out as described previously (Dhar 
and Manina, 2015). Bacterial cultures were grown to mid-exponential phase (A600 nm = 0.5) and 
concentrated ten-fold by centrifugation. Bacterial clumps were excluded by filtering through a 5 µm 
filter and the suspension comprising predominantly of single cells were assembled in a microfluidic 
device. Imaging of the bacteria was carried out using a 100x oil-immersion phase objective (Olympus 
Plan Semi Apochromat, 1.3 NA) on a Deltavision PersonalDV inverted microscope (GE Healthcare) 
fitted with an environmental chamber set at 37
0
C. Fresh 7H9 medium (supplemented with either 3 
µg/ml APYS1, during the drug exposure period or 2 µg/ml anhydrotetracycline for conditional 
depletion of Wag31 in the wag31 Tet-OFF strain was pumped through the device at a flow-rate of 15 
µl/min using a syringe pump. Imaging was carried out at 30 min or 60 min intervals in case of wag31 
Tet-OFF and H37Rv, respectively, on the phase channel. In case of the M. tuberculosis strain 
expressing Wag31-GFP, images were captured once every 24h, on the phase and FITC channels 
(Excitation filter 490/20, Emission filter 528/38). About 50-70 distinct positions in the microfluidic 
device were imaged in a typical experiment. Images were processed and movies assembled using 
Softworx 4.1 (Applied Precision, GE Healthcare) or ImageJ v 1.47n (Rasband, 2015). 
Additional methods and details of the chemical syntheses of APYS1-3 are described in the 
Supplementary Methods section. 
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Table 1. Summary of APYS1 susceptibility of different M. tuberculosis clones and constructs, and 
their wag31 genotype. 
Strain/Isolate MIC
 (µM) 
Base mutation in 
wag31 
Amino acid 
substitution in Wag31 
H37Rv 0.3-0.6 WT WT 
ARC1 6.25-12.5 c637g R213G 
ARC2 6.25-12.5 c601a Q201K 
ARC3 6.25-12.5 c637t R213C 
ARC4 100 a602g Q201R 
ARC5 50-100 g570c K190N 
ARC6 25 g570t K190N 
ARC7 6.25-12.5 g638t R213L 
ARC8 25-50 g570t K190N 
ARC9 25-50 g570t K190N 
ARC10 25-50 c625t L209F 
ARC11 12.5-25 c622t R208G 
H37Rv::Rec-wag31
Q201R
 >100 a602g Q201R 
H37Rv:: pTT1B (control) 0.2-0.5 WT WT 
H37Rv:: pTTwag31 0.2-0.5 WT + WT WT + WT 
H37Rv:: pTTwag31
Q201R
 0.2-0.5 WT + a602g WT + Q201R 
ARC4:: pTT1B (control) 100 a602g Q201R 
ARC4:: pTTwag31 1.56 a602g + WT Q201R + WT 
ARC4:: pTTwag31
 Q201R
 100 a602g + a602g Q201R + Q201R 
Erdman 0.3-0.6 WT WT 
Erdman::wag31-gfp 0.3-0.6 WT + WT-gfp WT + WT-gfp 
H37Ra 0.25-0.5 WT WT 
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Figure Legends 
Figure 1: Structures of the anti-tubercular aminopyrimidine-sulfonamides identified by phenotypic 
screening 
Figure 2: (A) A model summarising the multiple protein alignment of Wag31 from various rod-shaped 
bacteria (not Gram negative). There are three main conserved regions (CR1-3) (numbering for M. 
tuberculosis and B. subtilis indicated). The resistance determining region (RDR) shows the region 
where mutations were found in M. tuberculosis wag31 that confer resistance to APYS1, a region not 
found in the B. subtilis homolog. Threonine 73 (T73) represents the site of phosphorylation of M. 
tuberculosis Wag31. (B) The bases and amino acids in the RDR of wag31 (both in red) that were 
mutated in the eleven APYS1-resistant strains. (C) A multiple alignment of the RDR in a number of 
rod-shaped bacteria shows that this region is largely conserved in mycobacteria, carries multiple 
mutations in C. glutamicum and is mostly absent from other rod-shaped Gram-positive bacteria. Red 
asterisks represent the amino acids found to be mutated in APYS1-resistant M. tuberculosis. (D) A 
helical wheel representation of the RDR of Wag31 (amino acid 184-219) shows that the mutated 
residues (with dark edge) are located primarily on one side of the wheel 
(http://rzlab.ucr.edu/scripts/wheel). 
Figure 3: (A) The impact of conditional transcription repression of wag31 on the relative growth rate 
of wag31 Tet-OFF (open squares) and wag31 Tet-ON (black circles) as a function of the concentration 
of ATc in the culture medium. Data are the mean and SD of triplicate samples (see also Figure S3). (B) 
The 7-day APYS1 susceptibility of wag31 Tet-OFF grown in the absence (black circles) and presence 
of ATc (open circles [60 ng/ml]; open square [70 ng/mL]; open triangle [80 ng/mL]; and open 
diamond [100 ng/mL]). The data show that the ability to inhibit bacterial growth by APYS1 is not 
impacted by ATc-mediated silencing of wag31 expression. (C) Western blot analysis of ATc-
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dependent and time-dependent depletion of Wag31 in wag31 Tet-OFF. Strains were cultured in 
Middlebrook 7H9 broth and either left untreated (-) or exposed to ATc (500 ng/mL) (+) for the 
indicated length of time. Western Blots were probed with anti-Wag31 antibodies and anti-ThyX 
antibodies (loading control). 
Figure 4: Single-cell analysis of the effect of APYS1 on M. tuberculosis. Bacteria were cultured in a 
microfluidic device and imaged at 1 h intervals on the phase channel. Bacteria were exposed to 6 µM 
of APYS1 compound between 72-235 h. The images shown depict representative time-series 
snapshots of two positions in the microfluidic device that were imaged. Typically, in a time-lapse 
microscopy experiment, approximately 50-70 points are imaged. The white horizontal bar represents 
5 µm. The arrows point to swollen, polar regions of cells, whereas the arrowheads point to cells in 
which one side of the bacterium seems to elongate more than the opposite side, causing the tips to 
curl inwards. 
Figure 5: Exposure to APYS1 causes partial redistribution of Wag31-GFP in M. tuberculosis. Cells 
expressing Wag31-GFP were exposed to 6 µM APYS1 and imaged on day 0 (D0) and after 1, 2, 3 and 
5 days after exposure. Representative time-series snapshots of bacteria are shown. The red color 
represents the phase channel and the green channel represents the FITC channel (Wag31-GFP). On 
exposure to APYS1, the Wag31-GFP signal, which is usually a defined focus at the poles, becomes 
redistributed and spreads out at the poles followed by swelling of the poles (white arrows). The 
horizontal scale bar represents 3 µm. 
Figure 6: Single-cell analysis of effect of transcriptional silencing of wag31 in M. tuberculosis. 
wag31 Tet-OFF bacteria were grown in a microfluidic device and imaged at 30 min intervals on the 
phase channel. To knockdown the expression of Wag31 protein, the bacteria were exposed to 2 
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µg/ml ATc between 75-242 h. After a lag of 80-100 h, cells started to lyse and some of the new-pole 
siblings began to swell and become globular (white arrows). The images shown are representative 
time-series snapshots of two positions in the microfluidic device that were imaged. The white 
horizontal scale bar represents 5 µm. 
Figure 7. Scanning electron microscopy (SEM) images of (A and C) H37Rv in the absence of APYS1 
and (B, D, E, and F) H37Rv following 24 hrs of 3 µM APYS1 exposure. The images show a variety of 
polar deformations due to the compound. The white scale bar represents 1 µm. 
Table Legends 
Table 1. APYS1 susceptibility of different M. tuberculosis strains with altered wag31 genotypes. 
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Figure 2:  
Hydrophilic residues: circles (most hydrophilic (uncharged) residue in red, decreasing proportionally to the hydrophilicity), 
hydrophobic residues: diamonds (most hydrophobic residue is green, decreasing proportionally to the hydrophobicity). 
Zero hydrophobicity coded as yellow. The potentially charged residues are light blue. 
Page 30 of 35Molecular Microbiology
Figure 3:  
Page 31 of 35 Molecular Microbiology
Figure 4:  
Page 32 of 35Molecular Microbiology
Figure 5:  
Page 33 of 35 Molecular Microbiology
Figure 6:  
Page 34 of 35Molecular Microbiology
Figure 7. 
Page 35 of 35 Molecular Microbiology
Page 36 of 35Molecular Microbiology
